Bristol-Myers Squibb Company (BMY) FCF Payout Ratio: 42.85%
Is Bristol-Myers Squibb Company’s FCF payout ratio high or low?
Bristol-Myers Squibb Company's FCF payout ratio of 42.85% is 22% above its 5-year average of 34.99%, near the high end of its 5-year range (28.86%–39.28%).
The FCF payout ratio for Bristol-Myers Squibb Company (BMY) is 42.85%. It is above its 12-month average by 15.57% (37.08%).
BMY FCF Payout Ratio Chart
BMY Average FCF Payout Ratio Chart
BMY Current vs Average FCF Payout Ratio Chart
BMY FCF Payout Ratio Metrics
FCF PAYOUT RATIO
42.85%
FCF PAYOUT RATIO AVG TTM
37.08%
FCF PAYOUT RATIO AVG 3Y
37.61%
FCF PAYOUT RATIO AVG 5Y
34.99%
FCF PAYOUT RATIO AVG 10Y
61.91%
FCF PAYOUT RATIO AVG 15Y
61.85%
FCF PAYOUT RATIO AVG 20Y
77.33%
CURRENT VS TTM AVG
+15.57%
CURRENT VS 3Y AVG
+13.93%
CURRENT VS 5Y AVG
+22.46%
CURRENT VS 10Y AVG
-30.79%
CURRENT VS 15Y AVG
-30.72%
CURRENT VS 20Y AVG
-44.59%
Payout Ratio Comparison
FCF Payout Ratio
42.9%
Earnings Payout Ratio
72.3%
Dividend Yield
4.43%
FCF Yield
10.32%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $12.85B | $5.04B | 39.3% |
| 2024 | $13.94B | $4.86B | 34.9% |
| 2023 | $12.65B | $4.74B | 37.5% |
| 2022 | $11.95B | $4.63B | 38.8% |
| 2021 | $15.23B | $4.40B | 28.9% |
| 2020 | $13.30B | $4.08B | 30.6% |
| 2019 | $7.37B | $2.68B | 36.3% |
| 2018 | $6.12B | $2.61B | 42.7% |
| 2017 | $4.22B | $2.58B | 61.1% |
| 2016 | $1.84B | $2.55B | 138.2% |
| 2015 | $1.28B | $2.48B | 192.8% |
| 2014 | $2.62B | $2.40B | 91.5% |
| 2013 | $3.01B | $2.31B | 76.8% |
| 2012 | $6.39B | $2.29B | 35.8% |
| 2011 | $4.47B | $2.25B | 50.4% |
| 2010 | $4.07B | $2.20B | 54.1% |
| 2009 | $3.33B | $2.48B | 74.5% |
| 2008 | $2.77B | $2.46B | 89.0% |
| 2007 | $2.31B | $2.21B | 95.8% |
| 2006 | $1.29B | $2.20B | 170.5% |
| 2005 | $1.07B | $2.19B | 204.7% |
| 2004 | $2.37B | $2.17B | 91.8% |
| 2003 | $2.52B | $2.17B | 86.0% |
| 2002 | ($237.00M) | $2.17B | N/A (Loss) |
| 2001 | $4.38B | $2.14B | 48.8% |
| 2000 | $4.06B | $1.93B | 47.5% |
| 1999 | $3.52B | $1.71B | 48.6% |
| 1998 | $2.99B | $1.55B | 51.8% |
| 1997 | $1.71B | $1.51B | 88.6% |
| 1996 | $2.04B | $1.51B | 73.9% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Bristol-Myers Squibb Company FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company FCF Payout Ratio FAQ
- What is the FCF payout ratio for Bristol-Myers Squibb Company (BMY)?
- The FCF payout ratio for BMY stock is 42.85%.
- Is Bristol-Myers Squibb Company's FCF payout ratio high or low?
- Bristol-Myers Squibb Company's FCF payout ratio of 42.85% is 22% above its 5-year average of 34.99%, near the high end of its 5-year range (28.86%–39.28%).
- What is the TTM average FCF payout ratio for Bristol-Myers Squibb Company (BMY)?
- The TTM average FCF payout ratio for BMY stock is 37.08%.
- What is the 3Y average FCF payout ratio for Bristol-Myers Squibb Company (BMY)?
- The 3Y average FCF payout ratio for BMY stock is 37.61%.
- What is the 5Y average FCF payout ratio for Bristol-Myers Squibb Company (BMY)?
- The 5Y average FCF payout ratio for BMY stock is 34.99%.
- What is the 10Y average FCF payout ratio for Bristol-Myers Squibb Company (BMY)?
- The 10Y average FCF payout ratio for BMY stock is 61.91%.
- What is the 15Y average FCF payout ratio for Bristol-Myers Squibb Company (BMY)?
- The 15Y average FCF payout ratio for BMY stock is 61.85%.
- What is the 20Y average FCF payout ratio for Bristol-Myers Squibb Company (BMY)?
- The 20Y average FCF payout ratio for BMY stock is 77.33%.
Bristol-Myers Squibb Company FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 39.28% |
| 2024-12-31 | 34.88% |
| 2023-12-31 | 37.50% |
| 2022-12-31 | 38.78% |
| 2021-12-31 | 28.86% |
| 2020-12-31 | 30.64% |
| 2019-12-31 | 36.33% |
| 2018-12-31 | 42.73% |
| 2017-12-31 | 61.07% |
| 2016-12-31 | 138.20% |
| 2015-12-31 | 192.76% |
| 2014-12-31 | 91.46% |
| 2013-12-31 | 76.76% |
| 2012-12-31 | 35.76% |
| 2011-12-31 | 50.39% |
| 2010-12-31 | 54.14% |
| 2009-12-31 | 74.45% |
| 2008-12-31 | 88.97% |
| 2007-12-31 | 95.80% |
| 2006-12-31 | 170.47% |
| 2005-12-31 | 204.68% |
| 2004-12-31 | 91.85% |
| 2003-12-31 | 86.00% |
| 2001-12-31 | 48.80% |
| 2000-12-31 | 47.50% |
| 1999-12-31 | 48.56% |
| 1998-12-31 | 51.80% |
| 1997-12-31 | 88.65% |
| 1996-12-31 | 73.87% |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner